Cancer and cyclooxygenase-2 (COX-2) inhibition

Current Pharmaceutical Design

Volumn 10, Issue 6, 2004, Pages 627-634

  Evans, Jilly F ^a   Kargman, S L ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Pointe Claire   (Canada)

Author keywords

Angiogenesis; Cancer; Colorectal cancer; COX 2; Cox 2 inhibitors; Cyclooxygenase 2; NSAID; Prostaglandins

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DICLOFENAC; ENZYME INHIBITOR; FLUOROURACIL; FOLINIC ACID; INDOMETACIN; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; SULINDAC;

ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW CELL; CANCER MODEL; CANCER PREVENTION; CANCER RADIOTHERAPY; CARCINOGENESIS; CELLULAR IMMUNITY; CLINICAL STUDY; CLINICAL TRIAL; CORRELATION ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME LOCALIZATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HAND FOOT SYNDROME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; LUNG CANCER; MITOSIS INHIBITION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW; SKIN CANCER; STROMA CELL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 1442276970     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043453126     Document Type: Review

References (95)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol Nature (Lond.) 1971; 231: 232-5.
2. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-89.
3. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001; 108: 25-30.
4. Thun MJ, Henley SJ. Epidemiology of Nonsteroidal Antiinflammatory drugs and colorectal cancer. In COX-2 blockade in cancer prevention and therapy; Harris RE; Ed.; Humana Press: New Jersey, 2003; pp.35-55.
5. Harris RE. Epidemiology of breast cancer and nonsteroidal antiinflammatory drugs. In COX-2 blockade in cancer prevention and therapy; Harris RE; Ed.; Humana Press: New Jersey 2003, pp57-68.
6. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002; 9: 693-5.
7. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic and clinical issues. J Natl Cancer Inst 2002; 94: 252-66.
8. Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-72.
9. Bennett A, Civier A, Hensby CN, Melhuish PB, Stamford IF. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut 1987; 28: 315-8.
10. Hixson LJ, Albert DS, Krutzsch M, Einsphar J, Brendel L, Gross PH, et al. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidmiol. Biomarkers Prev. 1994; 3: 433-8.
11. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-6.
12. Lundholm K, Gelin J, Hyltander A, Lonnroth C, Sandstrom R, Svaninger G, et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 54: 5602-6.
13. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is upregulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-6.
14. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992; 267: 4338-44.
15. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc. Natl Acad Sci USA 1992; 89: 7384-8.
16. Smith WL, De Witt DL, Garavito RM. Cyclooxygenases: structural, cellular and molecular biology. Annu Rev Biochem 2000; 69: 145-82.
17. Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 1994; 13: 241-56.
18. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
19. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 2556-9.
20. Sharma RA, Gescher A, Plastaras JP, Leuratti C, Singh R, Gallacher-Horley B, et al. Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells. Carcinogenesis 2001; 22: 1557-60.
21. 2 treatment in human colon cancer cells. Cancer Res 1998; 58: 362-6.
22. Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, DuBois RN, et al. Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem 2000; 275: 6628-35.
23. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11-21.
24. δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61: 1733-40.
25. Williams CS, Tsujii M, Resse J, Dey SK, DuBois RN. Cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000; 105: 1589-94.
26. Shen H, Williams CS, Shao J, Liang P, DuBois RN, Beauchamp RD. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem 1998; 273: 22120-7.
27. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 2002; 62: 4903-8.
28. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275: 11397-403.
29. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 18563-9.
30. 2 and angiogenesis. Proc Soc Exp Biol Med 1983; 172: 214-8.
31. Murota S, Kanayasu T, Nakano-Hayashi J, Morita I. Involvement of eicosanoids in angiogenesis. In 'Advances in Prostaglandin, Thromboxane and Leukotriene Research'. Ed. Samuelsson B. 1990; pp, 623-626. Raven Press Ltd; New York.
32. Peterson HI. Tumor angiogenesis: inhibition by prostaglandin synthetase inhibitors. Anticancer Res 1986; 6: 251-3.
33. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashina S, Katori M. Cyclooxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000; 130: 641-9.
34. Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibit αVβ3 integrin-mediated and Cdc-42/Rac-dependent endothelial cell spreading, migration and angiogenesis. Nat Med 2001; 9: 1041-7.
35. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62: 625-31.
36. Dicker AP, Williams TL, Grant DS. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 2001; 24: 438-42.
37. Burd R, Choy H, Dicker A. Potential for inhibitors of cyclooxygenase-2 to enhance tumor radioresponse. In COX-2 blockade in cancer prevention and therapy; Harris RE, Ed.; Humana Press: New Jersey, 2003; pp 301-11.
38. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cycloxygenase-2 inhibitors. Cancer Res. 2000; 60: 1306-11.
39. Goodwin JS, Cueppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983; 3: 295-315.
40. 2 that regulate cellular immune responses in the mouse. J Clin Invest 2001; 108: 1229-35.
41. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, et al. Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000; 164: 361-70
42. Braun DP, Ahn MC, Harris JE, Chu E, Casey L, Wilbanks G, et al. Sensitivity of tumoricidal function in macrophages from different anatomical sites of cancer patients to modulation of arachidonic acid metabolism. Cancer Res 1993; 53: 3362-8.
43. Lang S, Lauffer L, Clausen C, Lohr I, Schmitt B, Holzel D, et al. Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor. FASEB J 2003; 17: 286-8.
44. Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 2000; 156: 545-53.
45. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. J Am Med Assoc 1999; 282: 1254-7.
46. Zhang H, Sun X-F. Overexpression of cylooxygenase-2 correlates with advanced stages of colorectal cancer. Am. J Gastroenterology 2002; 97: 1037-41.
47. Hull MA, Fenwick SW, Chapple KS, Scott N, Toogood GF, Lodge JP. Cyclooxygenase-2 expression in colorectal cancer liver metastases. Clin Exp Metastasis 2000; 18: 21-7.
48. 716 knockout mice by inhibition of cyclooxygenase-2 (COX-2). Cell 1996; 87: 803-9.
49. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. 2000; 60: 5040-4.
50. Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
51. Trifan OC, Durham WF, Salazar VS, Horton J, Levin BD, Zweifel BS, et al. Cyclooxygnease-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 2002; 62: 5778-84
52. Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003; 63: 586-92.
53. Fenwick SW, Lodge JPA, Toogood GJ, Hull MA. A randomized, placebo-controlled study of the effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastasis proliferation, apoptosis and angiogenesis. Gastroenterology, 2003; In Press.
54. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. Cyclooxygenase-2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 2000; 118: 487-96.
55. Van Rees BP, Saukkonen K, Ristimaki A, Polkowski W, Tytgat GN, Drillenberg P, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002; 196: 171-9.
56. Zimmerman KC, Sarbia M, Weber A-A, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204.
57. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, Anderson MA, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122: 1101-12.
58. Kaur BS, Khamnehei N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase-2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002; 123: 60-7.
59. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 632-5.
60. Richards JA, Petrel TA, Brueggemeier RW. Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol 2002; 80: 203-12.
61. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis. Anticancer Res 2001; 21: 3425-32.
62. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 2002; 62: 5405-7.
63. Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC. Cyclooxygnease-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett 2002; 184: 7-12.
64. Dore M, Cote LC, Mitchell A, Sirois J. Expression of prostaglandin G/H synthase type 1, but not type 2, in human ovarian adenocarcinomas. J Histochem Cytochem 1998; 46: 77-84.
65. Matsumoto Y, Ishiko O, Deguchi M, Nakagawa E, Ogita S. Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med 2001; 8: 31-6.
66. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003; 63: 906-11.
67. Fang HY, Lin TS, Lin JP, Wu YC, Chow KC, Wang LS. Cyclooxygenase-2 in human non-small cell lung cancer. Eur J Surg Oncol 2003; 29: 171-7.
68. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models. Cancer Res 2000; 60: 6045-51.
69. Hida T, Kozaki K, Ito H, Miyaishi,O, Tatematsu Y, Suzuki T, et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase-2 inhibitor, JTE-522, and conventional anticancer drugs. Clin Cancer Res 2002; 8: 2443-7.
70. Kelloff GF, Steele VE, Sigman CC. Chemoprevention of cancer by NSAIDs and selective COX-2 blockade. In COX-2 blockade in cancer prevention and therapy; Harris RE, Ed.; Humana Press: New Jersey, 2003; pp.279-300.
71. Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002; 62: 3395-401.
72. Bol DK, Rowley RB, Ho CP, Pilz B, Dell J, Swerdel M, et al. Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res 2002; 62: 2516-21.
73. Fischer SM. Is cyclooxygenase-2 important in skin carcinogenesis? J Environ Pathol Toxicol Oncol 2002; 21: 183-91.
74. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer JL, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the developmeat of skin cancer. Carcinogenesis 1998; 19: 723-9.
75. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999; 20: 1939-44.
76. Solaraze (diclofenac sodium) Gel USPI, 2000.
77. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 73-78.
78. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000; 89: 589-596.
79. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, et al. Cyclooxygenase-2 is upregulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 2001; 61: 8617-8623.
80. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003: 191: 125-135.
81. Tucker ON, Dannenberg AJ, Yang EK, Zhan F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999; 59: 987-90.
82. Tseng WW, Deganutti A, Chen MM, Saxton RE, Liu CD. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slow tumor growth in human pancreatic cancer. J Gastrointest Surg 2002; 6: 838-43.
83. Chu J, Lloyd FL, Trifan OC, Knapp B, Rizzo MT. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. MolCancer Ther 2003; 2: 1-7.
84. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Semin Radiat Oncol 2001; 11: 290-9.
85. Kishi K, Peterson S, Peterson C, Hunter N, Mason K, Masferrer JL, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000; 60: 1326-31.
86. Raju U, Nakata E, Yang P, Newman RA, Ang KK, Milas L. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations. Int J Radiat Oncol Biol Phys 2002; 54: 886-94.
87. Pyo H, Choy H, Amorino GP, Kim J-S, Cao Q, Hercules SK, et al. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 2001; 7: 2998-3005.
88. Mann M, Sheng H, Shan J, Williams CS, Piacane PI, Sliwkowski MX, et al. Targeting cyclooxygenase-2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001; 120: 1713-9.
89. Sabino MA, Ghilardi JR, Jongen JL, Keyser CP, Luger NM, Mach DB, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 2002; 62: 7343-9.
90. Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and anti-tumor activity. Oncology 2002; 16: 31-7.
91. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC, et al. Cyclooxygenase-2, P-gylcoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res 2001; 21: 2141-7.
92. Porras A, Ko A, Larson P, Agrawal N, Woolf E, Ebel D, et al. Single and multiple pharmacokinetics [PK] of rofecoxib [R] in healthy subjects. Clin Pharm Ther 2000; 67: 137.
93. Anderson WF, Umar A, Viner JL, Hawk ET. The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Design 2002; 8(12): 1035-62.
94. Chauhan DP. Chemotherapeutic potential of curcumin for colorectal cancer. Curr Pharm Design 2002; 8(19): 1695-706.
95. Sobal G, Sinzinger H. Prostaglandins and lipid modification. Curr Pharm Design 2001; 7(6): 461-74.